Because the increasing complexity of the supply chain, serious practical questions about where it starts and ends, and precisely where control must be focused to guarantee quality all the way from ingredients to the final medicine. The more global and complex the distribution network, the more difficult it is to ensure that goods follow approved routes and are transported by approved and trained delivery drivers. It is essential that records are properly maintained and quality is assured at every point along the pharmaceutical supply chain.

The global growth of counterfeiting not only of finished products but also of APIs is a major issue for the industry.

• Counterfeit drugs worth more than €86 million a year – JUST IN IRELAND

The implementation of GDP is essential for keeping counterfeits out of the legitimate supply chain/distribution network, and lapses in GDP can leave any pharmaceutical supply chain vulnerable to counterfeits.




Hence, Good Distribution Practice (GDP) remains an essential aspect of compliance for all pharmaceutical products as raw material and products are transported and delivered on a global and local basis.
Newsletters Newsroom Suppliers and Services Directory